This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • AKT Inhibitor in Oestrogen Positive Breast Cancer ...
Clinical trial

AKT Inhibitor in Oestrogen Positive Breast Cancer (STAKT)

Read time: 1 mins
Last updated:16th Jan 2014

To compare the effect of four and a half days treatment of a range of doses of AZD5363 on selected markers of the AKT pathway and anti-proliferation compared with placebo in oestrogen receptor positive breast cancers.

To assess the tolerability of four and a half days treatment of AZD5363

Category Value
Study start date 2014-01-16

View full details